Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 13/20 | 0.65 |
| ▸ | GRIN1 | Q05586 | 13/20 | 0.65 |
| ▸ | GRIN2B | Q13224 | 13/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.45 |
| ▸ | FLT1 | P17948 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16626960 | 0.85 | NOTUM (0.56) | RXRAGRIN1GRIN2BKCNH2FLT1 | |
| SCHEMBL16626941 | 0.85 | P2RX7 (0.56) | RXRAGRIN1GRIN2B | |
| SCHEMBL19876881 | 0.81 | TDP1 (0.46) | RXRAGRIN1GRIN2BKCNH2 | |
| SCHEMBL24336729 | 0.81 | MAPT (0.46) | RXRAGRIN1GRIN2B | |
| SCHEMBL19889344 | 0.81 | RXRA (0.59) | RXRAGRIN1GRIN2B | |
| SCHEMBL19219453 | 0.79 | RXRA (1.00) | RXRAGRIN1GRIN2B | |
| SCHEMBL16626930 | 0.78 | NOTUM (0.47) | RXRAGRIN1GRIN2B | |
| SCHEMBL19876933 | 0.77 | MAOA (0.45) | RXRAGRIN1GRIN2B | |
| SCHEMBL12766882 | 0.76 | RXRA (0.53) | RXRAGRIN1GRIN2BKCNH2FLT1 | |
| SCHEMBL29574404 | 0.76 | RXRA (0.44) | RXRAGRIN1GRIN2BKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10227327-B2 | Inhibitors of metallo-beta-lactamase (MBL) comprising a zinc chelating moiety | Universitetet | Oslo (NO) | 2019-03-12 | — | — | US | disclosed |
| US-20160244431-A1 | Inhibitors of Metallo-Beta-Lactamase (MBL) Comprising a Zinc Chelating Moiety | UNIVERSITETET I OSLO (NO) | 2016-08-25 | — | — | US | disclosed |
| US-20160244431-A1 | Inhibitors of Metallo-Beta-Lactamase (MBL) Comprising a Zinc Chelating Moiety | UNIVERSITETET I OSLO (NO) | 2016-08-25 | — | — | US | disclosed |
| WO-2015049546-A1 | INHIBITORS OF METALLO-BETA-LACTAMASE (MBL) COMPRISING A ZINC CHELATING MOIETY | UNIVERSITETET I OSLO (NO) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244431-A1 | Inhibitors of Metallo-Beta-Lactamase (MBL) Comprising a Zinc Chelating Moiety | SLC30A6, DDO, SLC30A7 | RXRA 4511/4885GRIN1 1664/4885GRIN2B 1513/4885 |
| US-10227327-B2 | Inhibitors of metallo-beta-lactamase (MBL) comprising a zinc chelating moiety | SLC30A6, DDO, SLC30A7 | RXRA 4511/4885GRIN1 1664/4885GRIN2B 1513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.